Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
作者： P G Rose , J A Blessing , A R Mayer , H D Homesley
DOI: 10.1200/JCO.1998.16.2.405
关键词: Paclitaxel 、 Etoposide 、 Surgery 、 Chemotherapy 、 Carcinoma 、 Ovarian carcinoma 、 Gynecologic oncology 、 Oral administration 、 Urology 、 Medicine 、 Toxicity
摘要: PURPOSEA phase II trial was conducted to determine the activity of prolonged oral etoposide in platinum-resistant and platinum-sensitive ovarian carcinoma.PATIENTS AND METHODSPlatinum-resistant disease defined as progression on platinum-based chemotherapy or recurrence within 6 months completing therapy. The starting dose 50 mg/m2/d (30 for prior radiotherapy) 21 days, every 28 days. A escalation a maximum 60 prescribed.RESULTSOf 99 patients entered, 97 were assessable toxicity 82 response. Among 41 26.8% response rate (7.3% complete [CR] 19.5% partial [PR] rate) occurred. median duration 4.3 (range, 1.3 8.7), progression-free interval (PFI) 5.7 0.8 30.8+), survival time 10.8 1.9 45.8). Twenty-five had also previously received paclitaxel; which eight (3...
sci-hub.se 参考文章(29)
MJ Ratain, LS Kaminer, JD Bitran, RA Larson, MM Le Beau, C Skosey, S Purl, PC Hoffman, J Wade, JW Vardiman, Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. ,vol. 70, pp. 1412- 1417 ,(1987) , 10.1182/BLOOD.V70.5.1412.BLOODJOURNAL7051412
Jack Yalowich, Bonnie Glisson, Warren Ross, Tom Rowe, Leroy Liu, Role of Topoisomerase II in Mediating Epipodophyllotoxin-induced DNA Cleavage Cancer Research. ,vol. 44, pp. 5857- 5860 ,(1984)
K R Hande, M G Krozely, F A Greco, J D Hainsworth, D H Johnson, Bioavailability of low-dose oral etoposide. Journal of Clinical Oncology. ,vol. 11, pp. 374- 377 ,(1993) , 10.1200/JCO.1993.11.2.374
P I Clark, M L Slevin, S P Joel, R J Osborne, D I Talbot, P W Johnson, R Reznek, T Masud, W Gregory, P F Wrigley, A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. Journal of Clinical Oncology. ,vol. 12, pp. 1427- 1435 ,(1994) , 10.1200/JCO.1994.12.7.1427
G J Creemers, G Bolis, M Gore, G Scarfone, A J Lacave, J P Guastalla, R Despax, G Favalli, R Kreinberg, S Van Belle, I Hudson, J Verweij, W W Ten Bokkel Huinink, Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. Journal of Clinical Oncology. ,vol. 14, pp. 3056- 3061 ,(1996) , 10.1200/JCO.1996.14.12.3056
R. de Wit, M.E.L. van der Burg, A.v.d. Gaast, A. Logmans, G. Stoter, J. Verweij, Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Annals of Oncology. ,vol. 5, pp. 656- 657 ,(1994) , 10.1093/OXFORDJOURNALS.ANNONC.A058942
A P Kudelka, D Tresukosol, C L Edwards, R S Freedman, C Levenback, P Chantarawiroj, C Gonzalez de Leon, E E Kim, T Madden, B Wallin, M Hord, C Verschraegen, M Raber, J J Kavanagh, Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. Journal of Clinical Oncology. ,vol. 14, pp. 1552- 1557 ,(1996) , 10.1200/JCO.1996.14.5.1552
P J Hoskins, K D Swenerton, Oral etoposide is active against platinum-resistant epithelial ovarian cancer. Journal of Clinical Oncology. ,vol. 12, pp. 60- 63 ,(1994) , 10.1200/JCO.1994.12.1.60
M Markman, W Hoskins, RESPONSES TO SALVAGE CHEMOTHERAPY IN OVARIAN CANCER: A CRITICAL NEED FOR PRECISE DEFINITIONS OF THE TREATED POPULATION Journal of Clinical Oncology. ,vol. 10, pp. 513- 514 ,(1992) , 10.1200/JCO.1992.10.4.513
S P Joel, R Shah, P I Clark, M L Slevin, Predicting etoposide toxicity: relationship to organ function and protein binding. Journal of Clinical Oncology. ,vol. 14, pp. 257- 267 ,(1996) , 10.1200/JCO.1996.14.1.257